Please use this identifier to cite or link to this item:
Title: The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma
Authors: Shaib, Walid L
Nammour, Jean Paul A
Gill, Harpaul
Mody, Mayur
Saba, Nabil F
Affiliations: Faculty of Medicine 
Keywords: Esophageal cancer
Immune therapy
Issue Date: 2016-01-14
Publisher: National Library of Medicine
Part of: Journal of Clinical Medicine
Volume: 5
Issue: 11
The prognosis of esophageal cancers is poor and novel approaches are urgently needed. Despite improvements in outcomes with transtuzumab and ramucirumab, these improvements added an average of only 2 to 3 months with a median overall survival reported to be around 1 year. Comprehensive genomic sequencing has defined some molecular alterations with potential targets, but the majority of patients still do not benefit from druggable targets. Breakthroughs in immune checkpoint blockade have provided new therapeutic options in many cancers. Programmed death ligand 1 (PDL1) overexpression, a possible biomarker predicting response to immune checkpoint inhibitors, approaches forty percent in esophageal and gastric cancers. Translational and molecular studies have shown that esophageal cancers are possible candidate malignancies for immune checkpoint inhibition. In this review, we plan to highlight the mechanisms, preclinical, and early clinical data that provide insight on the role of immune therapeutics in esophageal cancers.
ISSN: 2077-0383
DOI: 10.3390/jcm5110100
Open URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Aug 13, 2022

Record view(s)

checked on Aug 14, 2022

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.